	US 11,739,154 B2
	AXL-specific antibodies and uses thereof
Kevin Henry, Ottawa (CA); Maria Luz Jaramillo, Montreal (CA); Colin Roger Mackenzie, Ottawa (CA); and Anne Marcil, Pierrefonds (CA)
Assigned to NATIONAL RESEARCH COUNCIL OF CANADA, Ottawa (CA)
Appl. No. 16/646,823
Filed by National Research Council of Canada, Ottawa (CA)
PCT Filed Sep. 10, 2018, PCT No. PCT/CA2018/051108 § 371(c)(1), (2) Date Mar. 12, 2020, PCT Pub. No. WO2019/051586, PCT Pub. Date Mar. 21, 2019.
Claims priority of provisional application 62/557,870, filed on Sep. 13, 2017.
Prior Publication US 2020/0277386 A1, Sep. 3, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 49/00 (2006.01); C12N 5/16 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 47/6803 (2017.08); A61K 49/00 (2013.01); A61P 35/00 (2018.01); C12N 5/16 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)]

23 Claims

1. An isolated or purified antibody that specifically binds to an epitope in an immunoglobulin-like (IgL) domain of human AXL ectodomain (ECD) wherein said antibody comprises:

Variable light chain (VL) CDR1, CDR2, and CDR3 sequences according to SEQ ID NOs: 80, 81, and 82, respectively; and

Variable heavy chain (VH) CDR1, CDR2, and CDR3 sequences according to SEQ ID NOs: 77, 78, and 79, respectively.